【レポートの概要(一部)】
1. Report Overview
1.1 The Companion Diagnostics Market Overview
1.2 Companion Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Companion Diagnostics
2.1 The Foundation of Personalised Medicine
2.2 Personalised Medicine: Changing the Patient Treatment Paradigm
2.3 In Vitro Diagnostic (IVD) Tests
2.3.1 Companion Diagnostics: A Type of IVD
2.3.2 Differences between Companion Diagnostics and Theranostics
2.3.3 Biomarkers to Companion Diagnostics
2.3.4 Genomic Biomarkers
2.3.5 Genomic Oncology Biomarkers
2.4 Regulations in the Companion Diagnostics Market
2.4.1 FDA’s Final Guidance on Companion Diagnostics
2.4.2 LDTs: A Changing Landscape
2.5 Encouraging the Contemporaneous Development of Companion Diagnostics
3. The World Companion Diagnostics Market, 2016-2026
3.1 Scope and Limitations
3.2 The Global Companion Diagnostics Market, 2014 and 2015
3.3 The Global Companion Diagnostics Market Sales Forecast, 2016-2026
3.4 Companion Diagnostics: Growth Outpacing the Rest of the IVD Market
3.5 Companion Diagnostics: Increasing Market Share of the IVD Market
3.6 The Companion Diagnostics Market by Submarket, 2014
3.7 Theranostics: Fastest Growing Segment of the CDx Market
3.8 Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2015-2025
4. Leading National Markets for Companion Diagnostics, 2016-2026
4.1 The Leading National Markets for Companion Diagnostics: Led by 3 Dominant Markets in 2014 & 2015
4.2 The Leading National Markets for Companion Diagnostics Sales Forecast, 2016-2026
4.2.1 Changing Market Shares of Leading National Markets, 2016-2026
4.3 The US Companion Diagnostics Market Sales Forecast, 2016-2026
4.3.1 The US Will Continue to Dominate the Market
4.4 The EU5 Companion Diagnostics Sales Market, 2014
4.4.1 The EU5 Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.2 Changing Market Shares of the EU5 Companion Diagnostics Market
4.4.3 The German Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.4 The French Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.5 The Italian Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.6 The Spanish Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.7 The UK Companion Diagnostics Market Sales Forecast, 2016-2026
4.5 The Japanese Companion Diagnostics Market Sales Forecast, 2016-2026
4.5.1 Japan’s Medical Technology Regulatory Process Reducing Time to Market
4.6 The Chinese Companion Diagnostics Market Sales Forecast, 2016-2026
4.6.1 Cancer Rates will Drive Adoption of Companion Diagnostic Tests
4.7 The Indian Companion Diagnostics Market Sales Forecast, 2016-2026
4.8 The Brazilian Companion Diagnostics Market Sales Forecast, 2016-2026
4.9 The Russian Companion Diagnostics Market Sales Forecast, 2016-2026
4.10 The South Korean Companion Diagnostics Market Sales Forecast, 2016-2026
4.11 The Rest of the World Companion Diagnostics Market Sales Forecast, 2016-2026
5. The Companion Diagnostics Market: Marketed Products and Pipeline Partnerships
5.1 Biomarkers: At the Forefront of Companion Diagnostics Development
5.2 US FDA Approved Companion Diagnostic Tests, 2016
5.3 Oncology Continues to Dominate the R&D Pipeline of Companion Diagnostics
5.4 Expensive Cancer Therapies Encourages the Development of CDx
5.5 Companion Diagnostic/Pharma Partnerships, 2013-2014
6. Business Models and Stakeholders in the Companion Diagnostics Market
6.1 Business Models for the Development of Companion Diagnostics
6.1.1 The Partnership Model is the Most Practiced Method
6.1.2 The Stand-Alone Model: Licensing an IP
6.1.3 The One Stop Shop Model: An Approach by Big Pharma
6.1.4 Using Contract Diagnostics Organisations (CDO): An Emerging Trend
6.2 Factors Driving Companies to Enter the Companion Diagnostics Market
6.3 Stakeholders Influencing the Companion Diagnostics Market
6.3.1 Pharmaceutical Companies and Diagnostic Manufacturers
6.3.2 Regulatory Authorities
6.3.3 Testing Laboratories
6.3.4 Physicians and Patients
6.3.5 Payers
6.4 Companion Diagnostics Competitive Landscape, 2016
7. Leading Companies in the Companion Diagnostics Market 2015
7.1 Roche: Global Diagnostics Leader
7.1.1 Ventana Medical Systems (Roche)
7.1.2 Sales and Recent Performance Analysis, 2014
7.1.3 Roche Diagnostics by Region, 2014
7.1.4 Roche: Internal Growth
7.1.5 Approval of Tarceva and Cobas EGFR Mutation Test
7.1.6 Roche’s Portfolio of Companion Diagnostic Project Pipeline and Marketed Companion Diagnostics, 2015
7.1.7 Ventana Companion Diagnostics: Robust New Prototype Assays
7.1.8 Recent Companion Diagnostic External Collaborations, 2014-2015
7.1.8.1 Ventana/Genmab
7.1.8.2 Ferring/ Roche: CDx Development for Infertility Treatment
7.1.8.3 MedImmune (AstraZeneca)/Ventana: Assay for NSCLC Targeted Clinical Trials
7.1.8.4 Merck/Ventana: CDx for an Undisclosed Target
7.1.8.5 AstraZeneca/Roche: CDx to Support Target Drug AZD9291
7.1.8.6 Boehringer Ingelheim/Roche
7.1.8.7 ImmunoGen/ Ventana
7.1.8.8 Foundation Medicine/Roche
7.1.9 Roche: Major M&A Activity and Strategic Partnerships Strengthen Position as Diagnostic Market Leader
7.1.9.1 Genia Acquisition to Strengthen DNA Sequencing Capabilities
7.1.9.2 IQuum Acquisition Allows Movement into POC MDx Market
7.1.9.3 Seragon Acquisition Strengthens Leading Position in Oncology
7.1.9.4 Santaris Acquisition Enchances Roche’s Position in RNA-Targeted Drugs Market
7.1.9.5 Bina Acquisition Brings Big Data Solution to Support NGS Development
7.1.9.6 Dutalys Acquisition Enhances Roche’s mAB Portfolio
7.1.9.7 Ariosa Acquisition Adds NIPT to Diagnostic Portfolio
7.1.9.8 Foundation Medicine Deal Enhances Personalised Medicine Capabilities for Oncology
7.1.9.9 Signature and CAPP Acquisitions Strengthen Circulating DNA Testing Abilities
7.1.9.10 GENEWEAVE and Kapa Acquisitions Help Cement Roche’s Position as the Market Leader
7.2 Qiagen N.V.: Leading CDx Collaborator with Pharmaceutical Companies
7.2.1 Sales and Recent Performance Analysis, 2010-2015
7.2.2 Qiagen Sales By Region
7.2.3 Companion Diagnostics Collaboration Agreements with Pharma, 2015
7.2.3.1 Collaboration with Eli Lilly
7.2.3.2 Collaboration with AstraZeneca
7.2.3.3 Collaboration with Astellas Pharma
7.2.3.4 Collaboration with Novartis
7.2.3.5 Collaboration with Array BioPharma
7.2.3.6 Collaboration with Protagen
7.3 Abbott Molecular: An Established Competitor
7.3.1 Sales and Recent Performance Analysis, 2012-2015
7.3.2 Abbott Molecular: Expansive Oncology Biomarker Pipeline
7.3.3 Recent Activity and Collaborations
7.3.3.1 Collaboration with Merck
7.3.3.2 Collaborative Efforts with Idera
7.3.3.3 Collaboration with AstraZeneca
7.4 Agilent Technologies (Dako)
7.4.1 Life Sciences and Diagnostics Business
7.4.2 Agilent Life Sciences and Diagnostics, Sales and Recent Performance Analysis, 2015
7.4.3 Agilent: Next Generation Sequencing Platforms
7.4.4 Recent Companion Diagnostic Collaborations
7.4.4.1 Agilent/ Merck: Several Cancer Collaborations
7.4.4.2 Agilent/Pfizer: An Ongoing Collaboration
7.4.4.3 Agilent/Bristol-Myers Squibb
7.5 Myriad Genetics
7.5.1 Acquisition of Myriad RBM: Increases the Company’s Market Share of Companion Diagnostics
7.5.2 Companion Diagnostic Service Offerings
7.5.3 Sales and Recent Performance Analysis, 2013-2014
7.5.3.1 myRisk: Next Generation Hereditary Cancer Testing
7.5.4 Myriad Genetics Recent Collaborations
7.5.4.1 Myriad/AstraZeneca: Premarket Approval Application
7.5.4.2 Acquisition of Crescendo Bioscience: Entry into the Autoimmune Market
7.5.4.3 Myriad/ TESARO Companion Collaboration
7.5.4.4 Collaboration with AbbVie
7.6 BioMérieux
7.6.1 Sales and Recent Performance Analysis, 2010-2015
7.6.2 Sales by Region, 2014
7.6.3 Sales by Technology, 2015
7.6.4 Companion Diagnostics: Recent M&A Activity & Collaboration
7.6.4.1 Collaboration with Gilead Sciences
7.6.4.2 Collaboration with Ipsen
7.6.4.3 Collaboration with Merck
7.6.4.4 Collaborations with GSK and Novartis
7.6.4.5 Mergers, Acquisitions and Collaborations
7.6.5 bioTheranostics: Subsidiary for Oncology Diagnostics
7.7 Thermo Fisher Scientific
7.7.1 Sales and Recent Performance Analysis, 2013-2014
7.7.1.1 Thermo Fisher Scientific Sales by Region, 2015
7.7.2 Recent Collaborations and Acquisitions
7.7.2.1 Acquisition of Life Technologies
7.7.2.2 Acquisition of Prionics
7.7.2.3 Acquisition of Advanced Scientifics, Inc.
7.7.2.4 Acquisition of Alfa Aesar
7.7.2.5 Affymetrix: Thermo Fisher’s Next Target
7.7.2.6 Thermo Fisher: Developing a ‘Universal’ Companion Diagnostics Using Next Generation Sequencing
7.7.2.7 Thermo Fisher: Life Technologies Collaborates with Merck Serono
7.7.2.8 Thermo Fisher Scientific Collaboration with Pfizer and Novartis to Offer NGS-Based Companion Test for NSCLC
8. Qualitative Analysis of the Companion Diagnostics Market, 2016-2026
8.1 SWOT Analysis of the Companion Diagnostics Market
8.2 Strengths
8.2.1 A CDx Strategy Decreases the Length of Approval Process
8.2.2 Premium Prices for Companion Diagnostics
8.2.3 A CDx Development Strategy Can Generate More Effective Drugs
8.2.4 Therapeutics Tied with CDx can have Safer Profiles
8.2.5 Reducing the Cost of Healthcare
8.2.6 Increased Regulatory Scrutiny on Marketed Drugs
8.2.7 Targeted Therapies Will Drive the CDx Market
8.3 Weaknesses
8.3.1 Reimbursement Challenges
8.3.2 Lack of Clear Regulatory Guidelines
8.3.3 Capital Intensity is High
8.4 Opportunities
8.4.1 Fast-growing Emerging Markets
8.4.2 Next Generation Sequencing
8.4.3 Many New CDx/ Pharma Company Partnerships
8.5 Threats
8.5.1 Complex Business Models and Business Partnerships
8.5.2 Medical Device Excise Tax
8.6 Porter’s Five Forces Analysis of the Companion Diagnostics Market
8.6.1 Rivalry Among Competitors [High]
8.6.2 Power of Suppliers [High]
8.6.3 Power of Buyers [Medium]
8.6.4 Threat of New Entrants [Medium]
8.6.5 Threat of Substitutes [High]
9. Conclusions
9.1 Overview
9.2 Theranostics: A Fast Growing Market
9.3 Leading Companion Diagnostic Companies
9.4 Pharmaceutical/Diagnostic Partnership Model
9.5 Oncology is the Leading Therapy Area Driving Companion Diagnostics
9.6 Commercial Drivers of the Companion Diagnostics Market
9.7 Commercial Restraints of the Companion Diagnostics Market
9.8 Concluding Remarks
10. Glossary
Appendix
Visiongain’s Bespoke Research Service
Some Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form
【レポート販売概要】
■ タイトル:コンパニオン診断(CDx)の世界市場予測2016-2026■ 英文:The Companion Diagnostics (CDx) Market Forecast 2016-2026
■ 発行日:2016年3月
■ 調査会社:visiongain
■ 商品コード:VGAIN6041538
■ 調査対象地域:グローバル
- アイデンティティ及びアクセス管理の世界市場予測(~2021年)“The identity & access management market is projected to grow at a CAGR of 12.9% between 2016 and 2021” The identity & access management market is estimated to grow from USD 8.09 billion in 2016 to USD 14.82 billion by 2021, at a CAGR of 12.9% between 2016 and 2021. Companies are seeking ways to increase revenue by countering cybersecurity threats and addressing the issues of management, auditing, …
- 半導体製造用材料の世界市場:シリコンウェーハ、フォトマスク、フォトレジスト、湿潤化学物質、CMPスラリー/パッド、ガス、スパッタターゲット材Technavios research analyst predicts the global semiconductor fabrication material market to grow steadily at a CAGR of around 4% during the forecast period. The growth of the global semiconductor industry is the primary growth driver for this market. The rising demand for high-performance devices with improved speed and capacity has positively impacted the demand for silicon, reflective coating, …
- 高級アイウェアの世界市場2019-2023About this market Growing trend for personalized luxury eyewear to drive market growth. The desire for premium eyeglasses and sunglasses among potential customers is growing in European countries such as Germany, the UK, France, Spain, and Italy. Some of the popular premium brands of sunglasses are sold by LVMH. LUXOTTICA GROUP. Safilo Group, and Essilor. Despite low volume sales relative to the m …
- 通信用プロセッサの世界市場2015-2019About Communication Processor Communication processors are used in embedded systems, such as data or voice switches, routers, and wireless base stations, and enhance the functionalities of general-purpose processors. In 2014, the market was dominated by the telecommunication segment. Technavio’s analysts forecast that the global communication processors market will grow at a CAGR of 4.86%, by reve …
- Simponi(潰瘍性大腸炎):市場分析と予測(~2022)Simponi (Ulcerative Colitis) - Forecast and Market Analysis to 2022 Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting …
- 世界の機能安全市場:提供別(コンポーネント(安全センサー、プログラマブル安全システム、最終制御要素)、サービス)、システム別(ESD、TMC、F&G、HIPPS、BMS)、産業別(石油&ガス、化学、発電)、地域別“Functional safety market to exhibit significant growth during 2019–2024” The functional safety market is estimated to grow from USD 4.6 billion in 2019 to USD 7.1 billion by 2024, at a CAGR of 8.8%. The key factors driving the market’s growth include strict mandates for safety regulations, surging demand for safety systems in the oil & gas industry, high requirement for reliable safety systems to …
- ヨーロッパ主要国の麻酔器市場EU5 Anesthesia Machines Market Outlook to 2021 Summary GlobalData’s new report, "EU5 Anesthesia Machines Market Outlook to 2021", provides key market data on the EU5 Anesthesia Machines market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments - Portable Anesthesia Delivery Machines, Stand Alone Anesthesia Deliver …
- パッケージド廃水処理(PWWT)の世界市場2015-2019About packaged wastewater treatment plants Packaged wastewater treatment (PWWT) plants are pre-engineered and custom designed treatment facilities that are used to treat wastewater on a relatively lower scale for small communities, municipalities, and industries. These plants are typically constructed in a factory and simply transported and installed on the site of the requirement. They are design …
- Sectra AB:市場シェア分析Sectra AB Market Share Analysis Summary GlobalData’s new report, “Sectra AB Market Share Analysis” provides in-depth information on Sectra AB’s market position in the medical imaging information systems market. The report also provides data and information on the overall competitive landscape within the medical imaging information systems market. The report is supplemented with global corporate-le …
- アジア太平洋の定置式発電機市場About generators Generators are devices that convert mechanical energy into electric energy. The source of mechanical energy can be internal combustion engine, hand crank, compressed air, or reciprocating steam engine. Internal combustion engine uses diesel, gasoline, propane gas, and natural gas to produce mechanical energy, and this mechanical energy is converted into electric energy with the he …
- グリーン・バイオ系溶剤の世界市場の動向分析:製品別(バイオアルコール、バイオグリコール、バイオジオール、乳酸エステル、大豆メチル)、用途別(塗料、工業用および家庭用クリーナー、接着剤、印刷インキ、化粧品)、セグメント予測、2013 – 2024The global green & bio-based solvents market is expected to reach a market size of USD 13.74 billion by 2024, according to a new report by Grand View Research, Inc. The green & bio-based solvents market is expected to witness significant growth over the forecast period owing to the stringent regulations imposed on chemical-based industrial solvents in relation to VOC emissions. The rising demand f …
- シリコンカーバイドの世界市場分析:製品別(ブラックシリコンカーバイド、グリーンシリコンカーバイド)、エンドユーザー別(鉄鋼・エネルギー、自動車、航空宇宙・航空、軍事・防衛、医療・ヘルスケア、電子・半導体)、セグメント予測、-2020The Global Silicon Carbide Market is expected to reach USD 4.49 billion by 2020, according to a new study by Grand View Research, Inc. Positive outlook on steel manufacturing, for which SiC is used as a deoxidizing agent is expected to drive silicon carbide demand. In addition, silicon carbide is an essential element in the manufacturing of semiconductors which is expected to witness significant g …
- 世界の微生物資材市場:種類別(農業微生物資材、サイレージ微生物資材)、微生物別(細菌、真菌)、作物種類別(油料種子&豆類、シリアル&穀物、果物&野菜、飼料)、地域別“The inoculants market is projected to grow at a CAGR of 6.9%, in terms of value.” The inoculants market is estimated to reach USD 808 million in 2019 and is projected to account for USD 1,207 million by 2025, recording a CAGR of 6.9% during the forecast period. In South America, countries such as Brazil and Argentina are projected to offer high growth prospects in the coming years, as they are ra …
- 治療薬の世界市場分析:製品別(消耗品、機器、データ管理サービス)、技術別(イムノアッセイ、プロテオーム技術)、薬品別(抗てんかん剤、抗生物質、免疫抑制剤、抗不整脈剤)、エンドユーザー別(病院研究室、私設研究室)、セグメント予測The global therapeutic drug monitoring market is expected to reach over USD 3.37 billion by 2024, according to a new report by Grand View Research, Inc. Recent technological advancements in the Point-of-Care (PoC) devices hold considerable transformative promises for the personalized predictive and preventive medicine. Therapeutic Drug Monitoring (TDM) forms a foundational part to the devising of …
- 世界の非破壊検査(NDT)機器市場動向(2012-2016)TechNavio's analysts forecast the Global Nondestructive Testing Equipment market to grow at a CAGR of 7.82 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rapid infrastructure development across the world. The Global Nondestructive Testing Equipment market has also been witnessing an increasing demand for nondestructive testing equipment from BRI …